Daniel Menichella is the President and Chief Executive Officer of Kaleido Biosciences, a clinical-stage healthcare company developing oral therapies.
Daniel Menichella is the President and Chief Executive Officer of Kaleido Biosciences, a clinical-stage healthcare company developing oral therapies for COVID-19 and microbiome-based treatments. He joined Kaleido Biosciences in an executive leadership role, with the company focusing on synthetic glycan therapies that modulate the microbiome to treat disease.
Full founder directory · Investor directory · Company funding database · Fundraising library